Pharmacokinetic and toxicity study of intravitreal erythropoietin in rabbits

Acta Pharmacologica Sinica

Volumn 29, Issue 11, 2008, Pages 1383-1390

  Zhang, Jing Fa ^a   Wu, Ya Lan ^a   Xu, Jing Ying ^a   Ye, Wen ^b   Zhang, Yu ^b   Weng, Huan ^b   Shi, Wo Dong ^a   Xu, Guo Xu ^c   Lu, Luo ^a   Dai, Wei ^a   Sinclair, Stephen H ^g   Li, Wei Ye ^a,d,g   Xu, Guo Tong ^a,e,f  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c SOOCHOW UNIVERSITY   (China)

^d PEKING UNION MEDICAL COLLEGE   (China)

^e Tongji Eye Institute   (China)

^f TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^g DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Erythropoietin; Intravitreal injection; Ocular toxicity; Pharmacokinetics

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TISSUE LEVEL; ELECTRORETINOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE EXAMINATION; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RABBIT; SLIT LAMP;

ANIMALS; CELL COUNT; ELECTRORETINOGRAPHY; ERYTHROPOIETIN, RECOMBINANT; HUMANS; MALE; MICROINJECTIONS; RABBITS; RETINA; VITREOUS BODY;

EID: 55149102448     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00885.x     Document Type: Article

References (23)

1. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002 47 Suppl 2 : S253 62.
2. Li W, Yanoff M, Jian B, He Z. Altered mRNA levels of antioxidant enzymes in pre-apoptotic pericytes from human diabetic retinas. Cell Mol Biol (Noisy-le-grand) 1999 45 : 59 66.
3. Zhang J, Wu Y, Jin Y, Ji F, Sinclair SH, Luo Y, et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci 2008 49 : 732 42.
4. Sharpies EJ, Thiemermann C, Yaqoob MM. Novel applications of recombinant erythropoietin. Curr Opin Pharmacol 2006 6 : 184 9.
5. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 2004 11 Suppl 1 : S37 44.
6. Xie Z, Wu X, Qiu Q, Gong Y, Song Y, Gu Q, et al. Expression pattern of erythropoietin and erythropoietin receptor in experimental model of retinal detachment. Curr Eye Res 2007 32 : 757 64.
7. Tsai JC, Wu L, Worgul B, Forbes M, Cao J. Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucoma. Curr Eye Res 2005 30 : 1025 31.
8. King CE, Rodger J, Bartlett C, Esmaili T, Dunlop SA, Beazley LD. Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection. Exp Neurol 2007 205 : 48 55.
9. Jolling K, Perez Ruixo JJ, Hemeryck A, Vermeulen A, Greway T. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci 2005 24 : 465 75.
10. Yoon WH, Park SJ, Kim IC, Lee MG. Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats. Res Commun Mol Pathol Pharmacol 1997 96 : 227 40.
11. Jurado Garcia JM, Torres Sanchez E, Olmos Hidalgo D, Alba Conejo E. Erythropoietin pharmacology. Clin Transl Oncol 2007 9 : 715 22.
12. Hanna L. Epoietin alfa (EPO) for anemia. BETA 1998 : 40 : 42.
13. Goy A, Belanger C, Casadevall N, Picard F, Guesnu M, Jaulmes D, et al. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome. Br J Haematol 1993 84 : 232 7.
14. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multi-center clinical trial. Ann Intern Med 1989 111 : 992 1000.
15. Kanbay M, Akcay A, Delibasi T, Uz B, Kaya A, Koca C, et al. Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure. Adv Ther 2007 24 : 346 52.
16. Luft FC. Erythropoietin and arterial hypertension. Clin Nephrol 2000 53 (1 Suppl) : S61 4.
17. Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. Eur J Clin Invest 2003 33 : 891 6.
18. Becerra SP, Amaral J. Erythropoietin-an endogenous retinal survival factor. N Engl J Med 2002 347 : 1968 70.
19. Song BJ, Cai H, Gomes N, Chang S, Tsai J, Forbes M, et al. Ocular Safety of Serial Intravitreal Injections of Recombinant Human Erythropoietin: A 7 Month Study in Rabbits [CD-ROM]. Fort Lauderdale: The Association for Research in Vision and Ophthalmology 2008.
20. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007 114 : 855 9.
21. Fauser S, Kalbacher H, Alteheld N, Koizumi K, Krohne TU, Joussen AM. Pharmacokinetics and safety of intravitreally delivered etanercept. Graefes Arch Clin Exp Ophthalmol 2004 242 : 582 6.
22. Boelaert JR, Schurgers ML, Matthys EG, Belpaire FM, Daneels RF, De Cre MJ, et al. Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 1989 9 : 95 8.
23. Sytkowski AJ, Lunn ED, Davis KL, Feldman L, Siekman S. Human erythropoietin dimers with markedly enhanced in vivo activity. Proc Natl Acad Sci USA 1998 95 : 1184 8.